Feasibility, reliability, and clinical validity of the test of attentional performance for Children (KiTAP) in fragile X syndrome (FXS)

Journal of Neurodevelopmental Disorders

Volumn 4, Issue 1, 2012, Pages 1-12

  Knox, Andrew ^a   Schneider, Andrea ^b,c   Abucayan, Floridette ^b   Hervey, Crystal ^a   Tran, Christina ^a   Hessl, David ^b,c   Berry Kravis, Elizabeth ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CLONIDINE; LITHIUM; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; VALPROIC ACID;

ABERRANT BEHAVIOR CHECKLIST COMMUNITY EDITION; ADOLESCENT; ADULT; ALERTNESS; ARTICLE; ATTENTION; BEHAVIOR ASSESSMENT SYSTEM FOR CHILDREN SECOND EDITION; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITION; CORRELATION COEFFICIENT; DISTRACTIBILITY; EXECUTIVE FUNCTION; FEASIBILITY STUDY; FEMALE; FRAGILE X SYNDROME; HUMAN; INHIBITION (PSYCHOLOGY); INTELLECTUAL IMPAIRMENT; MALE; PRESCHOOL CHILD; PSYCHOMETRY; RELIABILITY; REPRODUCIBILITY; SCHOOL CHILD; SCORING SYSTEM; TASK PERFORMANCE; TEST OF ATTENTIONAL PERFORMANCE FOR CHILDREN; VALIDATION STUDY; VALIDITY;

EID: 84861859102     PISSN: 18661947     EISSN: 18661955     Source Type: Journal    
DOI: 10.1186/1866-1955-4-2     Document Type: Article

References (30)

1. Hagerman PJ: The Fragile X prevalence paradox. J Med Genet 2008, 45:498-499.
2. Bagni C, Greenough WT: From mRNP trafficking to spine dysmorphogenesis: the roots of Fragile X syndrome. Nat Rev Neurosci 2005, 6:376-87.
3. Bassell GJ, Warren ST: Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 2008, 60:201-214.
4. Oostra BA, Willemsen R: FMR1: a gene with three faces. Biochim Biophys Acta 2009, 1790:467-477.
5. Reiss AL, Dant CC: The behavioral neurogenetics of Fragile X syndrome: analyzing gene-brain-behavior relationships in child developmental psychopathologies. Dev Psychopathol 2003, 15:927-68.
6. Hagerman RJ, Berry-Kravis E, Ono MY, Tartaglia N, Lachiewicz A, Kronk B, Delahunty C, Kauffman W, Hessl DR, Visootsak J, Picker J, Gane L, Tranfaglia M, Hatton D, Rivera S, Farzin F, Lemons-Chitwood K, Greiss-Hess L, Ferguson H: Advances in the treatment of Fragile X syndrome. J Pediatr 2009, 123:378-390.
7. Bear MF, Huber KM, Warren ST: The mGluR theory of Fragile X mental retardation. Trends Neurosci 2004, 27:370-77.
8. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP: Suppression of two major Fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 2005, 49:1053-66.
9. Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BJ, Chattarji S, Bear MF: Correction of Fragile X syndrome in mice. Neuron 2010, 56:955-962.
10. Wang LW, Berry-Kravis E, Hagerman RJ: Fragile X: leading the way for targeted treatments in autism. Neurotherapeutics 2010, 7:264-274.
11. Wilding J, Cornish K, Munir F: Further delineation of the executive function deficit in males with Fragile X syndrome. Neuropsychologia 2002, 40:1343-1349.
12. Hagerman RJ: Physical and behavioral phenotype. In Fragile X syndrome: Diagnosis, Treatment and Research. 3 edition. Edited by: Hagerman RJ, Hagerman PJ. Baltimore: The Johns Hopkins University Press; 2002:3-109.
13. Bailey DB, Raspa M, Olmsted M, Holiday DB: Co-occurring conditions associated with FMR1 gene variations: Findings from a national parent survey. Am J Med Genet 2008, 146A:2060-2069.
14. Amado-Boccara I, Daban C, Willard-Schroeder D, Krebs MO, Bourdel MC, Poirier MF: Attentional disorders - Working memory and schizophrenia - Comparison of treated and non treated patients. Eur Neuropsychopharm 1998, 8:249.
15. Delcker A, Wilhelm H, Timann D, Diener HC: Side effects from increased doses of carbamazepine on neuropsychological and posturographic parameters of humans. Eur Neuropsychopharm 1997, 7:213-218.
16. Hanisch C, Konrad K, Günther T, Herpertz-Dahlmann B: Age-dependent neuropsychological deficits and effects of methylphenidate in children with attention-deficit/hyperactivity disorder: a comparison of pre- and grade-school children. J Neural Transm 2004, 111:865-881.
17. Berry-Kravis E, Krause SE, Block SS, Guter S, Wuu J, Leurgans S, Decle P, Potanos K, Cook E, Salt J, Maino D, Weinberg D, Lara R, Jardini T, Cogswell J, Johnson S, Hagerman R: Effect of CX516, an AMPAmodulating compound, on cognition and behavior in Fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol 2006, 16:525-540.
18. Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, Hutchison J, Snape M, Tranfaglia M, Nguyen DV, Hagerman R: A pilot open label, single dose trial of fenobam in adults with Fragile X syndrome. J Med Genet 2009, 46:266-271.
19. Dykens EM, Hodapp RM, Ort S, Finucane B, Shapiro LR, Leckman JF: The trajectory of cognitive development in males with Fragile X syndrome. J Am Acad Child Adolesc Psychiatry 1989, 28:422-426.
20. Berry-Kravis E, Lara R, Kim O-K, Sumis A, Wuu J: Characterization of potential outcome measures for future clinical trials in Fragile X syndrome. J Autism Dev Disord 2008, 38:1751-1757.
21. Hooper SR, Hatton D, Sideris J, Sullivan K, Hammer J, Schaaf J, Mirrett P, Ornstein PA, Bailey DB Jr: Executive functions in young males with Fragile X syndrome in comparison to mental age-matched controls: Baseline findings from a longitudinal study. Neuropsychology 2008, 22:36-47.
22. Kaufmann L, Zieren N, Zotter S, Karall D, Scholl-Burgi S, Haberlandt E, Fimm B: Predictive validity of attentional functions in differentiating children with and without ADHD: a componential analysis. Dev Med Child Neurol 2010, 52:371-378.
23. Psychologische Testsysteme: KiTAP Test of Attentional Performance for Children. 2011 [http://www.psytest.net/index.php?page=KiTAP], Language.
24. Kaller T, Langguth N, Ganaschow R, Nachan B, Schulz KH: Attention and executive functioning deficits in liver-transplanted children. Transplantation 2010, 90:1567-1573.
25. Nicolescu R, Petcu C, Cordeanu A, Fabritius K, Schlumpf M, Krebs R, Kramer U, Winneke G: Environemental exposure to lead, but not other neurotoxic metals, relates to core elements of ADHD in Romanian children: performance and questionnaire data. Environ Res 2010, 110:476-483.
26. Reynolds CR, Kamphaus RW: BASC-2-2 Behavior Assessment System for Children San Antonio, TX: Pearson PsychCorp; 1992.
27. Aman M: Aberrant Behavior Checklist - Community East Aurora, NY: Slosson Educational Publications; 1994.
28. Sansone SM, Widaman KF, Hall SS, Reiss AL, Lightbody A, Kaufmann WE, Berry-Kravis E, Lachiewicz A, Brown EC, Hessl D: Psychometric study of the aberrant behavior checklist in Fragile X syndrome and implications for targeted treatment. J Autism Dev Disord 2011.
29. Sullivan K, Hatton DD, Hammer J, Sideris J, Hooper S, Ornstein PA, Bailey DB Jr: Sustained attention and response inhibition in boys with Fragile X syndrome: measures of continuous performance. Am J Med Genet B Neuropsychiatr Genet 2007, 144:517-532.
30. Van der Molen KJ, Huizinga M, Huizinga HM, Ridderinkhof KR, Van der Molen MW, Hamel BJ, Curfs LM, Ramakers GJ: Profiling Fragile X syndrome in males: strengths and weaknesses in cognitive abilities. Res Dev Disabil 2010, 31:426-439.